Latest News and Events

Exco InTouch's ePRO Seminars Highlight Growing Importance Of Electronic Communication in Clinical Trials

Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, announces that the company's recent Electronic Patient Reported Outcomes (ePRO) seminars highlighted the increasing shift from traditional methods of data collection in clinical trials towards electronic methods. The informative seminars entitled 'The Complete Patient Experience Throughout the Trial Lifecycle' took place in Philadelphia and London and demonstrated the benefits of using electronic technology (e.g. cell phones) for patient recruitment, retention and compliance during clinical trials.


The half-day seminars were co-hosted by Exco InTouch and ERT, a leading provider of centralized ECG and eClinical technology, ePRO and other services to the biopharmaceutical, medical device and related industries. Seminars in both London and Philadelphia venues were attended by over 40 delegates from small, medium and large pharma organisations and CRO companies. The seminars addressed the impact of new communication technologies on patient engagement in clinical trials and how these technologies have revolutionised data collection for pharmaceutical companies.

Several industry leaders attended the seminars to conduct discussions on the application of these methods for clinical trials, including a keynote address from Dr. Ken Kaitin, Director and Professor of Medicine Tufts Center for the Study of Drug Development at Tufts University, Massachusetts. Dr. Kaitin is an internationally recognized expert on the science of drug development processes in the pharmaceutical and biopharmaceutical industries. His address entitled 'Pharmaceutical Innovation at a Cross Roads: Economic and Political Perspectives on New Drug Development Process', explored the current economic, regulatory, and political challenges in developing new pharmaceutical products.  Representatives from global pharmaceutical companies also participated in the seminars including Mahnaz Asgharnejad, VP of Clinical Development at CeNeRx BioPharma, a biopharmaceutical company developing innovative treatments for diseases of the central nervous system. Dr. Asgharnejad discussed the application of ePRO to facilitate patient selection and monitoring in clinical trials.

During the seminars, Exco InTouch's representatives demonstrated through numerous case studies how their innovative portfolio of communication-based technologies benefits pharmaceutical companies by significantly improving patient recruitment, retention and compliance throughout the clinical trials process. The seminars highlighted how using methods of electronic communication to retrieve confidential patient information greatly improves the speed, accuracy and integrity of data. Several large pharmaceutical companies already employ Exco InTouch's cell phone-based technology as a simple and cost-effective way to retrieve data from patients while maintaining full compliance with strict industry regulations.





News Archive

Exco InTouch Success Stories - Testimonial

Follow us

InTouch Clinical - Secure and regulatory compliant mobile solutions automatically schedule and deliver text messages directly to patients and caregivers.

Secure & regulatory compliant mobile solutions which automatically schedule & deliver text messages to patient & caregiver cell phones

ePRO Cell - The world’s first validated eDiary solution on a mobile phone. Secure, smarter and easier to gather crucial PRO data.

The world’s first validated ePRO solution on a cell phone. A secure, smarter & easier method of collecting crucial PRO data

ePRO APP - A simpler, more efficient way to gather data from subjects, care givers and sites that is fast to set up and easy to use.

A simpler, more efficient way to gather PRO data from subjects, caregivers & sites, that is quick to set up & easy to use by all participants

InTouch Recruit - Enhancing recruitment into clinical trials allows sponsor companies to reduce time and ultimately to bring new drugs to market faster.

Enhancing clinical trials recruitment, allowing sponsor companies to reduce timelines & ultimately bring new drugs to market faster